Research Analysts Set Expectations for BioCardia Q1 Earnings

BioCardia, Inc. (NASDAQ:BCDA) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of BioCardia in a report released on Thursday, March 26th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.17) for the quarter. The consensus estimate for BioCardia’s current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for BioCardia’s Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.17) EPS and Q4 2026 earnings at ($0.18) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $25.00.

BioCardia Price Performance

Shares of NASDAQ BCDA opened at $1.18 on Friday. The company has a market capitalization of $12.52 million, a price-to-earnings ratio of -0.91 and a beta of 0.60. The business has a 50-day moving average of $1.24 and a two-hundred day moving average of $1.35. BioCardia has a 1 year low of $1.00 and a 1 year high of $3.20.

BioCardia (NASDAQ:BCDA) last issued its earnings results on Tuesday, March 24th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.14.

Institutional Investors Weigh In On BioCardia

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Cetera Investment Advisers purchased a new stake in BioCardia in the second quarter valued at $40,000. DRW Securities LLC purchased a new position in shares of BioCardia during the fourth quarter worth about $72,000. Finally, Geode Capital Management LLC grew its holdings in shares of BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after purchasing an additional 27,263 shares during the last quarter. 20.57% of the stock is currently owned by institutional investors and hedge funds.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.